U.S. market Closed. Opens in 2 days 1 hour 38 minutes

BCTX | BriaCell Therapeutics Corp. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for BCTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak.

Valuation (17%)

Company Industry
P/E Ratio (TTM) -2.33 -22.08
PEG Ratio (TTM) -0.05 15.66
P/S Ratio (TTM) N/A 49.38
P/B Ratio (TTM) -2.38 18.85
P/FCF Ratio (TTM) -1.03 -3.07
Price to 5YR AVG Earnings Ratio 15.18 -3.42
Price to 5YR AVG FCF Ratio -3.24 -9.04

Profitability (50%)

Company Industry
ROA (TTM) -97.99% -5.15%
ROE (TTM) 161.34% 16.37%
Net Profit Margin (TTM) N/A -2,030.32%
ROIC 5YR AVG 54.88% 15.65%

Growth (17%)

4QTR AVG 3YR AVG 5YR AVG
EPS 54.17% -34.90% -39.04%
Revenue N/A N/A N/A
Net Income 54.64% -74.25% -119.63%
Cash Flow -9.75% -166.69% -130.28%

Health (4%)

Company Industry
Current Ratio (TTM) 0.82 6.19
Quick Ratio (TTM) 0.82 5.91
D/E Ratio (TTM) N/A -15.10
Interest Coverage (TTM) 2.44 -1.60
Piotroski F-Score N/A 5
Altman Z-Score N/A 14.02
LTL to 5YR AVG FCF N/A 0.18
Shares Outstanding Growth 5YR AVG 167.08% 123.85%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙